PRMT5 Associates With the FOXP3 Homomer and When Disabled Enhances Targeted p185erbB2/neu Tumor Immunotherapy
Yasuhiro Nagai(University of Pennsylvania), Mark I. Greene(University of Pennsylvania), Taku Kambayashi(California University of Pennsylvania), Takuya Ohtani(University of Pennsylvania), Bin Li(Shanghai Jiao Tong University), Hongtao Zhang(Chinese Academy of Sciences), Yan Xiao(University of Pennsylvania), Mei Ji(Soochow University), Michael M. Goldberg, Yukinori Tanaka(University of Pennsylvania), Shigeyoshi Fujimoto(Takara (Japan)), Fuxiang Zhu(Shanghai Institutes for Biological Sciences)
Cited by 73
Related Papers
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649
ErbB receptors: from oncogenes to targeted cancer therapies
|Journal of Clinical Investigation|2007|578
Advances in clinical immunotherapy for gastric cancer
|Biochimica et Biophysica Acta (BBA) - Reviews on Cancer|2021|435
Magnetically Propelled Fish‐Like Nanoswimmers
|Small|2016|271